Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Glioblastoma 7Congenital Abnormalities 7Lymphoma, Non-Hodgkin 6Lymphoma, Mantle-Cell 6Gliosarcoma 6Burkitt Lymphoma 6Astrocytoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Myeloproliferative Disorders 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Oligodendroglioma 4Medulloblastoma 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Carcinoma, Renal Cell 4Breast Neoplasms, Male 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3

Interventions

Cetuximab 5Radiotherapy 4Docetaxel 3Cisplatin 3Sorafenib 2Sirolimus 2Platinum 2Magnetic Resonance Spectroscopy 2Erlotinib Hydrochloride 21,2-diaminocyclohexaneplatinum II citrate 2temsirolimus 1saracatinib 1ixabepilone 1fluoromisonidazole 1dehydroftorafur 1cediranib 1aldesleukin 1advexin 1adavosertib 1Vorinostat 1Sunitinib 1Soybean Proteins 1Rubidium-82 1Ritonavir 1Radiotherapy, Conformal 1Radiation 1Psychiatric Rehabilitation 1Nicotine 1Neoadjuvant Therapy 1N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Tongue Neoplasms × Vorinostat × Clear all
NCT01175980 2020-08-03

Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled 16 charts
Head & Neck

Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡